%0 Journal Article
%T Patient-derived xenograft models to optimize kidney cancer therapies
%A Patel, Avi
%A Cohen, Sarah
%A Moret, Ravan
%A Maresh, Grace
%A Gobe, Glenda C.
%A Li, Li
%J Translational Andrology and Urology
%D 2018
%B 2018
%9 
%! Patient-derived xenograft models to optimize kidney cancer therapies
%K 
%X Renal cell carcinoma (RCC) is the most common solid neoplasm of the adult kidney and has a high potential for developing metastatic spread. Approximately 25–30% of RCC patients have metastatic disease at presentation, and 30–40% of patients develop metastases after the initial diagnosis. Advanced renal cancer is a deadly and difficult-to-treat cancer. The 5-year survival rate of patients with metastatic disease is less than 10%, partly because RCC metastases become resistant to current therapies. Pre-clinical models may help to identify the optimum therapeutic options for individual patients. Here we reviewed various mouse xenograft methods for RCC treatment screening especially patient-derived orthotopic xenograft models. Advantages and disadvantaged of some of the models are also discussed.
%U https://tau.amegroups.org/article/view/22650
%P S156-S165
%@ 2223-4691